OBJECTIVE: To investigate the possible association of plasma levels of stromal cell-derived factor-1 (SDF-1; CXCL12) with clinical presentation of symptomatic coronary artery disease (CAD) and with cardiovascular risk factors. METHODS: A cath lab cohort of 492 consecutive patients with symptomatic CAD were recruited. Blood for plasma-SDF-1 determination was taken at the time of heart catheterization before percutaneous coronary intervention. RESULTS: Plasma-SDF-1 was significantly decreased in ST-elevation myocardial infarction (STEMI) compared to stable angina pectoris (SAP) or to non-ST-elevation myocardial infarction (NSTEMI) (SAP vs. NSTEMI vs. STEMI: [pg/ml]: mean ± SD: 2110 ± 562 vs. 2127 ± 467 vs. 1834 ± 377; P < 0.001) independent of cardiovascular therapy. A weak correlation was observed between cholesterol levels and plasma SDF-1 in the whole study population. Left ventricular function and diabetes mellitus associated with plasma SDF-1 levels in patients with NSTEMI, while among STEMI patients, those with hyperlipidemia presented with even further decreased SDF-1 levels. CONCLUSION: Plasma SDF-1 is significantly decreased in patients with STEMI, a fact which may reflect the importance of SDF-1 regulation in patients with acute myocardial infarction.
OBJECTIVE: To investigate the possible association of plasma levels of stromal cell-derived factor-1 (SDF-1; CXCL12) with clinical presentation of symptomatic coronary artery disease (CAD) and with cardiovascular risk factors. METHODS: A cath lab cohort of 492 consecutive patients with symptomatic CAD were recruited. Blood for plasma-SDF-1 determination was taken at the time of heart catheterization before percutaneous coronary intervention. RESULTS: Plasma-SDF-1 was significantly decreased in ST-elevation myocardial infarction (STEMI) compared to stable angina pectoris (SAP) or to non-ST-elevation myocardial infarction (NSTEMI) (SAP vs. NSTEMI vs. STEMI: [pg/ml]: mean ± SD: 2110 ± 562 vs. 2127 ± 467 vs. 1834 ± 377; P < 0.001) independent of cardiovascular therapy. A weak correlation was observed between cholesterol levels and plasma SDF-1 in the whole study population. Left ventricular function and diabetes mellitus associated with plasma SDF-1 levels in patients with NSTEMI, while among STEMI patients, those with hyperlipidemia presented with even further decreased SDF-1 levels. CONCLUSION: Plasma SDF-1 is significantly decreased in patients with STEMI, a fact which may reflect the importance of SDF-1 regulation in patients with acute myocardial infarction.
Authors: Subha Subramanian; Chunyu Liu; Abraham Aviv; Jennifer E Ho; Paul Courchesne; Pieter Muntendam; Martin G Larson; Susan Cheng; Thomas J Wang; Nehal N Mehta; Daniel Levy Journal: Arterioscler Thromb Vasc Biol Date: 2014-07-24 Impact factor: 8.311
Authors: Teresa Infante; Ernesto Forte; Concetta Schiano; Carlo Cavaliere; Carlo Tedeschi; Andrea Soricelli; Marco Salvatore; Claudio Napoli Journal: Am J Transl Res Date: 2017-07-15 Impact factor: 4.060
Authors: Karin Huizer; Andrea Sacchetti; Sigrid Swagemakers; Peter J van der Spek; Wim Dik; Dana A Mustafa; Johan M Kros Journal: Neurooncol Adv Date: 2020-04-01
Authors: Madhumita Chatterjee; Agnes Ehrenberg; Laura Mara Toska; Lisa Maria Metz; Meike Klier; Irena Krueger; Friedrich Reusswig; Margitta Elvers Journal: Int J Mol Sci Date: 2020-10-24 Impact factor: 5.923
Authors: Nicoleta Oprescu; Miruna Mihaela Micheu; Alexandru Scafa-Udriste; Nicoleta-Monica Popa-Fotea; Maria Dorobantu Journal: Ann Med Date: 2021-12 Impact factor: 4.709